Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

4.990 -0.180 (-3.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
ATRA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Atara Biotherapeutics, Inc. Investors - Contact Kirby McInerney LLP by May 22, 2026
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Deadline Approaching: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Law Offices of Frank R. Cruz Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Atara Biotherapeutics, Inc. (NASDAQ:ATRA) and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATRA
From DJS Law Group
Via Business Wire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
INVESTOR ALERT: Securities Class Action Filed Against Atara Biotherapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides a Business Update
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.